Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BeiGene Ltd ( (HK:6160) ) has issued an update.
BeOne Medicines Ltd., a corporation incorporated under the laws of Switzerland, announced the grant of Restricted Share Units (RSUs) under its 2016 Share Option and Incentive Plan. On August 8, 2025, the company’s compensation committee granted a total of 34,361 RSUs, representing 446,693 underlying shares, to 375 grantees. This grant accounts for approximately 0.03% of the total issued shares. The RSUs have a vesting period of four years, with 25% vesting annually, subject to continued employment. The announcement highlights the company’s commitment to incentivizing its workforce, potentially impacting employee retention and motivation.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$156.80 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,498,675
Technical Sentiment Signal: Buy
Current Market Cap: HK$273.7B
For an in-depth examination of 6160 stock, go to TipRanks’ Overview page.